143 related articles for article (PubMed ID: 38151160)
1. Examining the Features of Neuroleptic Malignant Syndrome in Anti-NMDA Receptor Encephalitis: A Case-Control Study.
Ramirez-Bermudez J; Restrepo-Martinez M; Espinola-Nadurille M; Martinez-Angeles V; Lopez-Hernandez JC; Hernandez-Vanegas LE; Martinez-Carrillo F; Ruiz-Garcia R; Rivas-Alonso V; Flores-Rivera J; Pollak TA
J Acad Consult Liaison Psychiatry; 2024; 65(3):222-230. PubMed ID: 38151160
[TBL] [Abstract][Full Text] [Related]
2. Anti-N-methyl-D-aspartate receptor encephalitis mimics neuroleptic malignant syndrome: case report and literature review.
Wang HY; Li T; Li XL; Zhang XX; Yan ZR; Xu Y
Neuropsychiatr Dis Treat; 2019; 15():773-778. PubMed ID: 31040676
[TBL] [Abstract][Full Text] [Related]
3. Reconsidering Rigidity in the Diagnosis of Neuroleptic Malignant Syndrome: A Case Report.
El Khoury R; Kassab A; Dagher R; Javelot H; El Chammay R; Richa S
J Psychiatr Pract; 2020 Jul; 26(4):320-323. PubMed ID: 32692129
[TBL] [Abstract][Full Text] [Related]
4. Agitation Management in Pediatric Males with Anti-N-Methyl-D-Aspartate Receptor Encephalitis.
Schumacher LT; Mann AP; MacKenzie JG
J Child Adolesc Psychopharmacol; 2016 Dec; 26(10):939-943. PubMed ID: 27992257
[TBL] [Abstract][Full Text] [Related]
5. Atypical neuroleptic malignant syndrome caused by olanzapine.
Nielsen J; Bruhn AM
Acta Psychiatr Scand; 2005 Sep; 112(3):238-40; discussion 240. PubMed ID: 16095481
[TBL] [Abstract][Full Text] [Related]
6. Neuroleptic malignant syndrome due to olanzapine.
Hall KL; Taylor WH; Ware MR
Psychopharmacol Bull; 2001; 35(3):49-54. PubMed ID: 12397878
[TBL] [Abstract][Full Text] [Related]
7. [Neuroleptic malignant syndrome and atypical antipsychotics: a brief review].
Khaldi S; Kornreich C; Choubani Z; Gourevitch R
Encephale; 2008 Dec; 34(6):618-24. PubMed ID: 19081460
[TBL] [Abstract][Full Text] [Related]
8. Anti-N-Methyl-D-Aspartate Receptor Encephalitis: A Potential Mimic of Neuroleptic Malignant Syndrome.
Rozier M; Morita D; King M
Pediatr Neurol; 2016 Oct; 63():71-72. PubMed ID: 27590992
[TBL] [Abstract][Full Text] [Related]
9. Ziprasidone- and lithium-induced neuroleptic malignant syndrome.
Borovicka MC; Bond LC; Gaughan KM
Ann Pharmacother; 2006 Jan; 40(1):139-42. PubMed ID: 16352776
[TBL] [Abstract][Full Text] [Related]
10. Antipsychotics leading to neuroleptic malignant syndrome in pregnancy.
Ghaffari N; Dossett E; Lee RH; Aghajanian P
Obstet Gynecol; 2012 Feb; 119(2 Pt 2):436-438. PubMed ID: 22270430
[TBL] [Abstract][Full Text] [Related]
11. Neuropsychiatric phenotypes of anti-NMDAR encephalitis: a prospective study.
Espinola-Nadurille M; Restrepo-Martínez M; Bayliss L; Flores-Montes E; Rivas-Alonso V; Vargas-Cañas S; Hernández L; Martínez-Juarez I; Gonzalez-Aguilar A; Solis-Vivanco R; Fricchione GL; Flores-Rivera J; Ramirez-Bermudez J
Psychol Med; 2023 Jul; 53(9):4266-4274. PubMed ID: 35534479
[TBL] [Abstract][Full Text] [Related]
12. Atypicality in presentation of neuroleptic malignant syndrome caused by olanzapine.
Mishra B; Mishra B; Sahoo S; Arora M; Khess CR
Indian J Med Sci; 2007 Oct; 61(10):570-3. PubMed ID: 17932448
[TBL] [Abstract][Full Text] [Related]
13. Neuroleptic malignant syndrome: case report and discussion.
Chandran GJ; Mikler JR; Keegan DL
CMAJ; 2003 Sep; 169(5):439-42. PubMed ID: 12952806
[TBL] [Abstract][Full Text] [Related]
14. Atypical neuroleptic malignant syndrome: diagnostic controversies and considerations.
Picard LS; Lindsay S; Strawn JR; Kaneria RM; Patel NC; Keck PE
Pharmacotherapy; 2008 Apr; 28(4):530-5. PubMed ID: 18363536
[TBL] [Abstract][Full Text] [Related]
15. Neuroleptic malignant syndrome in Mexico.
Montoya A; Ocampo M; Torres-Ruiz A
Can J Clin Pharmacol; 2003; 10(3):111-3. PubMed ID: 14506509
[TBL] [Abstract][Full Text] [Related]
16. [Case report: Neuroleptic malignant syndrome and diagnostic difficulties].
Khouri C; Planès S; Logerot S; Villier C; Mallaret M
Encephale; 2016 Jun; 42(3):277-80. PubMed ID: 26923996
[TBL] [Abstract][Full Text] [Related]
17. Response to benzodiazepines and the clinical course in malignant catatonia associated with schizophrenia: A case report.
Ohi K; Kuwata A; Shimada T; Yasuyama T; Nitta Y; Uehara T; Kawasaki Y
Medicine (Baltimore); 2017 Apr; 96(16):e6566. PubMed ID: 28422845
[TBL] [Abstract][Full Text] [Related]
18. Neuroleptic Malignant Syndrome in a Patient With Anti-N-Methyl-D-Aspartate Receptor Encephalitis: Case Report and Review of Related Literature.
Sarmiento RJC; Diestro JDB; Antonio AKD; Prado MB; Adiao KJB; Dioquino-Maligaso CP
Neurohospitalist; 2022 Jan; 12(1):80-85. PubMed ID: 34950391
[TBL] [Abstract][Full Text] [Related]
19. Psychiatric management of anti-NMDAR encephalitis: a cohort analysis.
Warren N; O'Gorman C; McKeon G; Swayne A; Blum S; Siskind D
Psychol Med; 2021 Feb; 51(3):435-440. PubMed ID: 31739809
[TBL] [Abstract][Full Text] [Related]
20. Catatonia in patients with anti-NMDA receptor encephalitis.
Espinola-Nadurille M; Flores-Rivera J; Rivas-Alonso V; Vargas-Cañas S; Fricchione GL; Bayliss L; Martinez-Juarez IE; Hernandez-Vanegas LE; Martinez-Hernandez R; Bautista-Gomez P; Solis-Vivanco R; Perez-Esparza R; Bustamante-Gomez PA; Restrepo-Martinez M; Ramirez-Bermudez J
Psychiatry Clin Neurosci; 2019 Sep; 73(9):574-580. PubMed ID: 31115962
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
